{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:13:42Z","timestamp":1788257622152,"version":"build-2803163510"},"reference-count":30,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T00:00:00Z","timestamp":1765065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100000001","name":"Alberta Cancer Foundation","doi-asserted-by":"publisher","award":["RK Dixon Family Award"],"award-info":[{"award-number":["RK Dixon Family Award"]}],"id":[{"id":"10.13039\/501100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Numerous studies have investigated the feasibility of home administration of bortezomib by nurses for the management of multiple myeloma. However, the impact of patient self-administration remains largely unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective of this study was to evaluate the impact and feasibility of patient self-administration of subcutaneous bortezomib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This prospective feasibility study aimed to assess the efficacy and safety of this intervention as well as quantify the impact on patients and their caregivers. Patient and caregiver satisfaction were assessed using validated questionnaires at monthly intervals. An analysis of both direct system and indirect patient costs was also conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Thirty-four patients received 1194 doses of bortezomib for self-administration over the study period. Patient self-administration was determined to have minimal impact of treatment efficacy, and with only 8 grade 3 higher adverse events occurring, there was no effect on safety since none were due to patient self-administration. Patient satisfaction with the intervention was highly rated with 99% of responses indicating that the patient would choose this clinic again. Caregiver quality of life remained stable for the duration of the intervention. Institutional cost savings totaled an estimated $CAD 1\u2009800\u2009000 over the trial period, while patients collectively saved an estimated $CAD 23\u2009000.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and relevance:<\/jats:title>\n                    <jats:p>Patient self-administration of bortezomib is efficacious, safe, cost effective, and was well received by both patients and caregivers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280251395061","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T07:59:46Z","timestamp":1765180786000},"page":"745-753","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["A Multicenter, Feasibility Study Exploring Self-Administration of Chemotherapy in the Home Environment: The EASE Study"],"prefix":"10.1177","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4442-2997","authenticated-orcid":false,"given":"Darius A.","family":"Ramrattan","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Chambers","sequence":"additional","affiliation":[{"name":"Pharmacy Services, Arthur Child Cancer Centre, Alberta Health Services, Calgary, AB, Canada"},{"name":"Cancer Care Alberta Pharmacy, Alberta Health Services, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Duggan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Arthur Child Cancer Centre, University of Calgary, Calgary, AB, Canada"},{"name":"Arthur Child Cancer Centre, Alberta Health Services, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0973-8857","authenticated-orcid":false,"given":"Joanne","family":"Hewitt","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada"},{"name":"Hematology Tumour Group, Cross Cancer Institute, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"McCulloch","sequence":"additional","affiliation":[{"name":"Department of Hematology, Arthur Child Cancer Centre, University of Calgary, Calgary, AB, Canada"},{"name":"Division of Hematology and Hematologic Malignancies, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irwindeep","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Yau","sequence":"additional","affiliation":[{"name":"Pharmacy Services, Arthur Child Cancer Centre, Alberta Health Services, Calgary, AB, Canada"},{"name":"Cancer Care Alberta Pharmacy, Alberta Health Services, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Tay","sequence":"additional","affiliation":[{"name":"Department of Hematology, Arthur Child Cancer Centre, University of Calgary, Calgary, AB, Canada"},{"name":"Arthur Child Cancer Centre, Alberta Health Services, Calgary, AB, Canada"},{"name":"Faculty of Medicine, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,7]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422"},{"key":"e_1_3_2_3_2","unstructured":"GCO. Multiple myeloma fact sheet. 2020. Accessed November 7 2025. https:\/\/gco.iarc.fr\/today\/en\/dataviz\/tables?mode=population&cancers=35&group_populations=0&multiple_populations=1"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08280-y"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102284"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"e_1_3_2_7_2","volume-title":"Clinical Practice Guideline on Multiple Myeloma: Transplant Eligible, Version 1","author":"Duggan P (Lead)","year":"2023","unstructured":"Duggan P (Lead), McCulloch S, Tay J, Tilley D. Clinical Practice Guideline on Multiple Myeloma: Transplant Eligible, Version 1. Cancer Care Alberta, Alberta Health Services; 2023."},{"key":"e_1_3_2_8_2","volume-title":"Clinical Practice Guideline on Multiple Myeloma: Transplant Ineligible, Version 1","author":"Duggan P (Lead)","year":"2023","unstructured":"Duggan P (Lead), McCulloch S, Tay J, Tilley D. Clinical Practice Guideline on Multiple Myeloma: Transplant Ineligible, Version 1. Cancer Care Alberta, Alberta Health Services; 2023."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01935"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2021.151176"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4155-8"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13690-024-01317-1"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2022.102199"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv563"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3363-3"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2009.09.003"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02671-2"},{"key":"e_1_3_2_18_2","unstructured":"National Association of Pharmacy Regulatory Authorities. Model standards for pharmacy compounding of hazardous sterile preparations. National Association of Pharmacy Regulatory Authorities; 2016."},{"key":"e_1_3_2_19_2","unstructured":"National Cancer Institute. Cancer therapy evaluation program. Published 2017. Accessed July 1 2025. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.html"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010816.pub2"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15245764"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.04.022"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.1721.1721"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-013-0520-8"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026407010614"},{"key":"e_1_3_2_26_2","article-title":"Meal and vehicle rates used to calculate travel expenses","author":"Government of Canada","year":"2025","unstructured":"Government of Canada. Meal and vehicle rates used to calculate travel expenses. Government of Canada; 2025.","journal-title":"Government of Canada;"},{"key":"e_1_3_2_27_2","article-title":"Cross Cancer Institute public parking","author":"Alberta Health Services","year":"2024","unstructured":"Alberta Health Services. Cross Cancer Institute public parking. Alberta Health Services; 2024.","journal-title":"Alberta Health Services;"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/1049909106289074"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.47649"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13316"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28469"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251395061","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280251395061","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251395061","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:20:47Z","timestamp":1788254447000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280251395061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,7]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/10600280251395061"],"URL":"https:\/\/doi.org\/10.1177\/10600280251395061","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,7]]}}}